In Health Impact Assessment (HIA), or priority-setting for health policy, effects of risk factors (exposures) on health need to be modeled, such as with a Markov model, in which exposure influences mortality and disease incidence rates. Because many risk factors are related to a variety of chronic diseases, these Markov models potentially contain a large number of states (risk factor and disease combinations), providing a challenge both technically (keeping down execution time and memory use) and practically (estimating the model parameters and retaining transparency). To meet this challenge, we propose an approach that combines micro-simulation of the exposure information with macro-simulation of the diseases and survival. This approach allows users to simulate exposure in detail while avoiding the need for large simulated populations because of the relative rareness of chronic disease events. Further efficiency is gained by splitting the disease state space into smaller spaces, each of which contains a cluster of diseases that is independent of the other clusters. The challenge of feasible input data requirements is met by including parameter calculation routines, which use marginal population data to estimate the transitions between states. As an illustration, we present the recently developed model DYNAMO-HIA (DYNAMIC MODEL for Health Impact Assessment) that implements this approach.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s13524-012-0122-z | DOI Listing |
J Hypertens
December 2024
Service de pharmacologie médicale et clinique, faculté de médecine, Centre Hospitalier Universitaire.
Objective: Ibrutinib has been the first Bruton tyrosine kinase inhibitor (BTKi) authorized for the treatment of B-cell lymphoproliferative disorders (B-LPDs). Numerous publications have confirmed the efficacy of this orally administrated drug in chemo-free regimens for B-LPDs. They also reported several adverse events (AE) associated with ibrutinib treatment.
View Article and Find Full Text PDFEnviron Sci Process Impacts
January 2025
Department of Otorhinolaryngology, No. 971 Hospital of People's Liberation Army Navy, Qingdao 266000, Shandong Province, China.
Hearing loss (HL) is an otolaryngology disease susceptible to environmental pollutants. Volatile organic compounds (VOCs), as a class of chemical pollutants with evaporation propensity, pose a great threat to human health. However, the association between VOCs and HL remains unclear.
View Article and Find Full Text PDFBr J Clin Pharmacol
January 2025
F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Aims: Crovalimab is a novel C5 inhibitor administered first intravenously and then subcutaneously in patients with paroxysmal nocturnal haemoglobinuria (PNH) naive to complement inhibition or switching from eculizumab or ravulizumab. Crovalimab showed efficacy and safety comparable to eculizumab in the pivotal COMMODORE 2 and supporting studies.
Methods: We characterized crovalimab pharmacokinetics and the relationship between exposure pharmacokinetic parameters and pharmacodynamic biomarkers, efficacy and safety endpoints using pooled data (healthy volunteers [n = 9], naive [n = 210] and switched [n = 211] patients).
J Eur Acad Dermatol Venereol
January 2025
Arbeitsgemeinschaft Nachhaltigkeit in der Dermatologie (AGN) e.V., Freiburg, Germany.
Hazards to human and planetary health are present at every stage of the plastic life cycle, yet plastic production is projected to triple by 2060. This review focuses on three key areas: the life cycle of plastic, the impact of microplastics and their associated chemicals, along with recommendations to reduce plastic use. In dermatology, micro- and nanoplastics are especially problematic as they are present in over 90% of personal care products.
View Article and Find Full Text PDFPediatr Obes
January 2025
Growth, Exercise, Nutrition and Development (GENUD) Research Group, Instituto Agroalimentario de Aragón (IA2), University of Zaragoza, Zaragoza, Spain.
Background: Although the genetic interplay with the environment has a major impact on obesity development, little is known on whether breastfeeding could modulate the genetic predisposition to obesity.
Objectives: To investigate whether breastfeeding attenuates the effect of an obesity genetic risk score (GRS) on adiposity in European adolescents.
Methods: Totally 751 adolescents from the Healthy Lifestyle in Europe by Nutrition in Adolescence (HELENA) cross-sectional study were included, divided according to breastfeeding status into never breastfed, 1-3 months and ≥4 months.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!